NCT03933319: Phase II Study of Pegylated Liposomal Doxorubicin (PLD) Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 70 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must either be 1 chemotherapy naïve in the metastatic setting or 2 had 1 prior regimen for MBC
Exclusions: Patients with symptomatic brain metastases

Comments are closed.

Up ↑